Tóm tắt
Các tác dụng phụ liên quan đến sự thiếu hụt estrogen của các liệu pháp điều trị ung thư hoặc của sự mãn kinh sớm ở những người có tiền căn ung thư thường được điều trị bằng estrogen đường toàn thân và đặt âm đạo trong dân số nói chung. Tuy nhiên, trong số những người có tiền sử ung thư nhạy cảm với hormone, vẫn còn chưa chắc chắn về sự an toàn của liệu pháp dựa trên hormone. Do đó, tổng quan này nhằm mục đích đánh giá tính an toàn và hiệu quả của các phương pháp điều trị bằng hormone cũng như các phương thức điều trị không dùng hormone. Các phương pháp điều trị không dùng hormone là chỉ định đầu tay cho tất cả bệnh nhân, tuy nhiên các bác sĩ cần phối hợp và thử nghiệm nhiều phương pháp để tìm ra phương pháp phù hợp nhất với từng bệnh nhân. Các liệu pháp sử dụng hormone liên quan estrogen và testosterone, mặc dù còn những quan ngại về vấn đề tái phát ung thư, tuy nhiên các nghiên cứu cho đến thời điểm hiện tại không cho thấy điều đó. Các phương pháp điều trị mới bao gồm ospemifene, laser tỏ ra hiệu quả, tuy nhiên cần nhiều nghiên cứu hơn để chứng minh tính hiệu quả lâu dài.
Tài liệu tham khảo
1. Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed 1 Aug 2023
2. Portman DJ, Gass MLS, Vulvovaginal atrophy terminology consensus conference panel (2014) genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the study of women’s sexual health and the North American Menopause Society. J Sex Med 11:2865–2872.
3. Sussman TA, Kruse ML, Thacker HL, Abraham J (2019) Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. J Oncol Pract 15:363–370.
4. Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Current Oncology 14:20–40.
5. Seav SM, Dominick SA, Stepanyuk B, et al (2015) Management of sexual dysfunction in breast cancer survivors: a systematic review. Womens Midlife Health 1:9.
6. Lee Y-K, Chung HH, Kim JW, et al (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors. Obstetrics & Gynecology 117:922–927.
7. Kim YH, Park S, Lee M, et al (2017) Effect of a pH-balanced vaginal gel on dyspareunia and sexual function in breast cancer survivors who were premenopausal at diagnosis. Obstetrics & Gynecology 129:870–876.
8. Hickey M, Marino JL, Braat S, Wong S (2016) A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 158:79–90.
9. Carter J, Baser RE, Goldfrank DJ, et al (2021) A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Supportive Care in Cancer 29:311–322.
10. Keshavarzi Z, Janghorban R, Alipour S, et al (2019) The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer. Supportive Care in Cancer 27:1325–1334.
11. Krychman M, Millheiser LS (2013) Sexual health issues in women with cancer. J Sex Med 10:5–15.
12. (2020) The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 27:976–992.
13. Goetsch MF, Lim JY, Caughey AB (2015) A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. Journal of Clinical Oncology 33:3394–3400.
14. Goetsch MF, Lim JY, Caughey AB (2014) Locating pain in breast cancer survivors experiencing dyspareunia. Obstetrics & Gynecology 123:1231–1236.
15. Manson JE, Goldstein SR, Kagan R, et al (2014) Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 21:911–916.
16. Lupo RMAN-CAM, Dains DJRJE, Madsen PRALT (2015) Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J Adv Pract Oncol 6(4):322-30.
17. (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet 394:1159–1168.
18. Melisko ME, Goldman ME, Hwang J, et al (2017) Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer. JAMA Oncol 3:313.
19. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of Oncology 17:584–587.
20. Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al (2020) Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause 27:526–534.
21. Biglia N, Peano E, Sgandurra P, et al (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecological Endocrinology 26:404–412.
22. Donders G, Bellen G, Neven P, et al (2015) Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. European Journal of Clinical Microbiology & Infectious Diseases 34:2023–2028.
23. Mazzarello S, Hutton B, Ibrahim MFK, et al (2015) Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 152:1–8.
24. Pfeiler G, Glatz C, Königsberg R, et al (2011) Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 14:339–344.
25. O’Meara ES, Rossing MA, Daling JR, et al (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. JNCI Journal of the National Cancer Institute 93:754–761.
26. Crandall CJ, Hovey KM, Andrews CA, et al (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 25:11–20.
27. Lyytinen H, Pukkala E, Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics & Gynecology 108:1354–1360.
28. Le Ray I, Dell’Aniello S, Bonnetain F, et al (2012) Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study. Breast Cancer Res Treat 135:603–609.
29. Harris BS, Bishop KC, Kuller JA, et al (2020) Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause 27:243–248.
30. Zuo SW, Wu H, Shen W (2018) Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors. Menopause 25:828–836.
31. Barton DL, Shuster LT, Dockter T, et al (2018) Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Supportive Care in Cancer 26:1335–1343.
32. Krychman ML, Stelling CJ, Carter J, Hudis CA (2007) A case series of androgen use in breast cancer survivors with sexual dysfunction. J Sex Med 4:1769–1774.
33. Dahir M, Travers-Gustafson D (2014) Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med 2:8–15.
34. Davis SR, Robinson PJ, Jane F, et al (2018) Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 103:4146–4154.
35. Lemke E, Madsen L, Dains J (2017) Vaginal testosterone for management of aromatase inhibitor–related sexual dysfunction: An integrative review. Oncol Nurs Forum 44:296–301.
36. Bell RJ, Rizvi F, Islam RM, Davis SR (2018) A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 25:704–709.
37. Witherby S, Johnson J, Demers L, et al (2011) Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I/II study. Oncologist 16:424–431.
38. Archer DF, Goldstein SR, Simon JA, et al (2019) Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 26:611–621.
39. Di Donato V, Schiavi MC, Iacobelli V, et al (2019) Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety. Maturitas 121:93–100.
40. Constantine G, Graham S, Koltun WD, Kingsberg SA (2014) Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med 11:1033–1041.
41. Jha S, Wyld L, Krishnaswamy PH (2019) The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: A systematic review and Meta-analysis. Clin Breast Cancer 19:e556–e562.
42. Athanasiou S, Pitsouni E, Douskos A, et al (2020) Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis. Lasers Med Sci 35:1–11.
43. Salvatore S, Nappi RE, Casiraghi A, et al (2021) Microablative fractional co2 laser for vulvovaginal atrophy in women with a history of breast cancer: A pilot atudy at 4-weekdFollow-up. Clin Breast Cancer 21:e539–e546.
44. Mothes AR, Runnebaum M, Runnebaum IB (2018) Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol 144:955–960.
45. Arêas F, Valadares ALR, Conde DM, Costa-Paiva L (2019) The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause. Menopause 26:1052–1058.
46. Quick AM, Zvinovski F, Hudson C, et al (2020) Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Supportive Care in Cancer 28:3669–3677.
47. Pagano T, De Rosa P, Vallone R, et al (2018) Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause 25:657–662.
48. Pagano T, De Rosa P, Vallone R, et al (2016) Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. Menopause 23:1108–1113.
49. Gambacciani M, Levancini M (2017) Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause 24:316–319.
50. Veron L, Wehrer D, Annerose-Zéphir G, et al (2021) Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. Breast Cancer Res Treat 188:501–509.
51. Quick AM, Zvinovski F, Hudson C, et al (2021) Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause 28:642–649.
52. Pieralli A, Fallani MG, Becorpi A, et al (2016) Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 294:841–846.
53. Gittens P, Mullen G (2019) The effects of fractional microablative CO 2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. Journal of Cosmetic and Laser Therapy 21:127–131.
2. Portman DJ, Gass MLS, Vulvovaginal atrophy terminology consensus conference panel (2014) genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the study of women’s sexual health and the North American Menopause Society. J Sex Med 11:2865–2872.
3. Sussman TA, Kruse ML, Thacker HL, Abraham J (2019) Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. J Oncol Pract 15:363–370.
4. Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Current Oncology 14:20–40.
5. Seav SM, Dominick SA, Stepanyuk B, et al (2015) Management of sexual dysfunction in breast cancer survivors: a systematic review. Womens Midlife Health 1:9.
6. Lee Y-K, Chung HH, Kim JW, et al (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors. Obstetrics & Gynecology 117:922–927.
7. Kim YH, Park S, Lee M, et al (2017) Effect of a pH-balanced vaginal gel on dyspareunia and sexual function in breast cancer survivors who were premenopausal at diagnosis. Obstetrics & Gynecology 129:870–876.
8. Hickey M, Marino JL, Braat S, Wong S (2016) A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 158:79–90.
9. Carter J, Baser RE, Goldfrank DJ, et al (2021) A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Supportive Care in Cancer 29:311–322.
10. Keshavarzi Z, Janghorban R, Alipour S, et al (2019) The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer. Supportive Care in Cancer 27:1325–1334.
11. Krychman M, Millheiser LS (2013) Sexual health issues in women with cancer. J Sex Med 10:5–15.
12. (2020) The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 27:976–992.
13. Goetsch MF, Lim JY, Caughey AB (2015) A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. Journal of Clinical Oncology 33:3394–3400.
14. Goetsch MF, Lim JY, Caughey AB (2014) Locating pain in breast cancer survivors experiencing dyspareunia. Obstetrics & Gynecology 123:1231–1236.
15. Manson JE, Goldstein SR, Kagan R, et al (2014) Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 21:911–916.
16. Lupo RMAN-CAM, Dains DJRJE, Madsen PRALT (2015) Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J Adv Pract Oncol 6(4):322-30.
17. (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet 394:1159–1168.
18. Melisko ME, Goldman ME, Hwang J, et al (2017) Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer. JAMA Oncol 3:313.
19. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of Oncology 17:584–587.
20. Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al (2020) Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause 27:526–534.
21. Biglia N, Peano E, Sgandurra P, et al (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecological Endocrinology 26:404–412.
22. Donders G, Bellen G, Neven P, et al (2015) Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. European Journal of Clinical Microbiology & Infectious Diseases 34:2023–2028.
23. Mazzarello S, Hutton B, Ibrahim MFK, et al (2015) Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 152:1–8.
24. Pfeiler G, Glatz C, Königsberg R, et al (2011) Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 14:339–344.
25. O’Meara ES, Rossing MA, Daling JR, et al (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. JNCI Journal of the National Cancer Institute 93:754–761.
26. Crandall CJ, Hovey KM, Andrews CA, et al (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 25:11–20.
27. Lyytinen H, Pukkala E, Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics & Gynecology 108:1354–1360.
28. Le Ray I, Dell’Aniello S, Bonnetain F, et al (2012) Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study. Breast Cancer Res Treat 135:603–609.
29. Harris BS, Bishop KC, Kuller JA, et al (2020) Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause 27:243–248.
30. Zuo SW, Wu H, Shen W (2018) Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors. Menopause 25:828–836.
31. Barton DL, Shuster LT, Dockter T, et al (2018) Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Supportive Care in Cancer 26:1335–1343.
32. Krychman ML, Stelling CJ, Carter J, Hudis CA (2007) A case series of androgen use in breast cancer survivors with sexual dysfunction. J Sex Med 4:1769–1774.
33. Dahir M, Travers-Gustafson D (2014) Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med 2:8–15.
34. Davis SR, Robinson PJ, Jane F, et al (2018) Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 103:4146–4154.
35. Lemke E, Madsen L, Dains J (2017) Vaginal testosterone for management of aromatase inhibitor–related sexual dysfunction: An integrative review. Oncol Nurs Forum 44:296–301.
36. Bell RJ, Rizvi F, Islam RM, Davis SR (2018) A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 25:704–709.
37. Witherby S, Johnson J, Demers L, et al (2011) Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: A phase I/II study. Oncologist 16:424–431.
38. Archer DF, Goldstein SR, Simon JA, et al (2019) Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 26:611–621.
39. Di Donato V, Schiavi MC, Iacobelli V, et al (2019) Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety. Maturitas 121:93–100.
40. Constantine G, Graham S, Koltun WD, Kingsberg SA (2014) Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med 11:1033–1041.
41. Jha S, Wyld L, Krishnaswamy PH (2019) The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: A systematic review and Meta-analysis. Clin Breast Cancer 19:e556–e562.
42. Athanasiou S, Pitsouni E, Douskos A, et al (2020) Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis. Lasers Med Sci 35:1–11.
43. Salvatore S, Nappi RE, Casiraghi A, et al (2021) Microablative fractional co2 laser for vulvovaginal atrophy in women with a history of breast cancer: A pilot atudy at 4-weekdFollow-up. Clin Breast Cancer 21:e539–e546.
44. Mothes AR, Runnebaum M, Runnebaum IB (2018) Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol 144:955–960.
45. Arêas F, Valadares ALR, Conde DM, Costa-Paiva L (2019) The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause. Menopause 26:1052–1058.
46. Quick AM, Zvinovski F, Hudson C, et al (2020) Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Supportive Care in Cancer 28:3669–3677.
47. Pagano T, De Rosa P, Vallone R, et al (2018) Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause 25:657–662.
48. Pagano T, De Rosa P, Vallone R, et al (2016) Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. Menopause 23:1108–1113.
49. Gambacciani M, Levancini M (2017) Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause 24:316–319.
50. Veron L, Wehrer D, Annerose-Zéphir G, et al (2021) Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. Breast Cancer Res Treat 188:501–509.
51. Quick AM, Zvinovski F, Hudson C, et al (2021) Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause 28:642–649.
52. Pieralli A, Fallani MG, Becorpi A, et al (2016) Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 294:841–846.
53. Gittens P, Mullen G (2019) The effects of fractional microablative CO 2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. Journal of Cosmetic and Laser Therapy 21:127–131.
Công trình này được cấp phép theo Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. .
Download
Dữ liệu downlad không hiện hữu.